- Home
- RIGL vs KE Comparison
RIGL vs KE Comparison
Compare RIGL & KE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | KE |
|---|---|---|
| Founded | 1996 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 586.4M |
| IPO Year | 2000 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RIGL | KE |
|---|---|---|
| Price | $40.45 | $25.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $45.67 | $28.00 |
| AVG Volume (30 Days) | ★ 386.8K | 215.1K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | 0.44 | ★ 0.78 |
| Revenue | $294,282,000.00 | ★ $1,486,727,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.75 | $4.57 |
| P/E Ratio | $93.09 | ★ $32.10 |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $18.70 | $18.04 |
| 52 Week High | $52.24 | $33.19 |
Technical Indicators
Market Signals| Indicator | RIGL | KE |
|---|---|---|
| Relative Strength Index (RSI) | 64.43 | 48.64 |
| Support Level | $40.05 | $23.65 |
| Resistance Level | $44.85 | $26.87 |
| Average True Range (ATR) | 1.82 | 1.09 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 58.00 | 42.00 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About KE Kimball Electronics Inc.
Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.